Filing Flows › Orchestra BioMed Holdings (OBIO) › Q1 2025
Orchestra BioMed Holdings (OBIO) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 12, 2025
Orchestra BioMed Holdings (OBIO) reported revenue of $868K for the first quarter 2025 (Q1 2025), +40% from a year earlier and +243% from the quarter before.
Orchestra BioMed Holdings, Q1 2025: revenue $868K (+40% year over year), net loss $18.8M, operating cash flow −$16.6M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $868K | +243% | +40% |
| Operating profit | −$18.9M | — | — |
| Net earnings | −$18.8M | — | — |
| Operating cash flow | −$16.6M | — | — |
What changed
Revenue was $868K in Q1 2025, up 40% year over year and up 243% from the previous quarter. Partnership revenue was the largest line at 84% of revenue. Partnership revenue added $235K year over year (up 47%), 95% of the total change.
Operating costs exceeded revenue by $18.9M, an operating margin of -2179.8%. Total costs grew 32% against revenue growth of 40%. The fastest-growing cost line was Research & development (+48%). The quarter ended with a net loss of $18.8M, wider than the previous quarter's $16.2M loss.
Operating cash flow was −$16.6M. Non-cash charges added back $83K of depreciation and $3.0M of share-based compensation. Working capital and other items used $909K. Capital expenditures of $112K exceeded it, leaving free cash flow of −$16.7M.
Questions
What was Orchestra BioMed Holdings' revenue in the first quarter 2025?
Orchestra BioMed Holdings (OBIO) reported revenue of $868K for the first quarter 2025 (Q1 2025), +40% from a year earlier and +243% from the quarter before.